Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1824842 | 0.85 | LMNA (0.47) | LMNAKDM4ECYP3A4ACHECYP4F2 | |
| SCHEMBL823757 | 0.82 | LMNA (0.52) | LMNAKDM4ECYP3A4ACHECYP4F2 | |
| SCHEMBL31621879 | 0.82 | LMNA (0.52) | LMNAKDM4ECYP3A4ACHECYP4F2 | |
| SCHEMBL7471140 | 0.82 | IDO1 (0.42) | LMNAKDM4EMAPTPOLBCA12 | |
| SCHEMBL27631287 | 0.81 | MEN1 (0.52) | LMNAMAPTMEN1KMT2A | |
| SCHEMBL27714304 | 0.81 | ACHE (0.49) | LMNAKDM4EACHEMAPTGLA | |
| SCHEMBL3234553 | 0.80 | KDM4E (0.53) | LMNAKDM4ECYP3A4CYP4F2CYP4A11 | |
| SCHEMBL24436689 | 0.79 | CYP3A4 (0.56) | LMNAKDM4ECYP3A4ACHECYP4F2 | |
| SCHEMBL11957057 | 0.79 | ACHE (0.59) | LMNAKDM4ECYP3A4ACHEMAPT | |
| SCHEMBL377673 | 0.79 | CYP3A4 (0.52) | LMNAKDM4ECYP3A4ACHEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552770-B2 | Compounds for treating respiratory disease | TMEM16A LIMITED (GB) | 2026-02-17 | — | — | US | disclosed |
| EP-4626880-A1 | COMPOUNDS FOR MODULATING HUR (ELAVL1) | Shanghai Degron Biomedical Technology Co., Ltd. (CN) | 2025-10-08 | — | — | EP | disclosed |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-10-07 | — | — | US | disclosed |
| WO-2025061148-A1 | HETEROARYL COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | 江苏恒瑞医药股份有限公司 | 2025-03-27 | — | — | WO | disclosed |
| CN-114616226-B | Pyridine derivatives as TMEM16A modulators for the treatment of respiratory disorders | TMEM16A有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-114269721-B | Compounds for the treatment of respiratory diseases | TMEM16A有限公司 | 2024-12-20 | — | — | CN | disclosed |
| US-12162863-B2 | Modulators of stimulator of interferon genes (STING) | Ryvu Therapeutics S.A. (PL) | 2024-12-10 | — | — | US | disclosed |
| WO-2024114639-A1 | COMPOUNDS FOR MODULATING HUR (ELAVL1) | SHANGHAI DEGRON BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024017201-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023142641-A1 | PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 成都苑东生物制药股份有限公司 | 2023-08-03 | — | — | WO | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| EP-1204659-B1 | SEROTONERGIC BENZOFURANS | LILLY CO ELI (US) | 2003-11-26 | — | — | EP | disclosed |
| EP-1204654-B1 | BENZOFURYLPIPERAZINES: 5-HT2C SEROTONIN RECEPTOR AGONISTS | LILLY CO ELI (US) | 2003-07-23 | — | — | EP | disclosed |
| EP-1204659-A2 | SEROTONERGIC BENZOFURANS | ELI LILLY AND COMPANY (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-1204654-A1 | BENZOFURYLPIPERAZINES AND BENZOFURYLHOMOPIPERAZINES: SEROTONIN AGONISTS | ELI LILLY AND COMPANY (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-1149085-A1 | AMINOALKYLBENZOFURANS AS SEROTONIN (5-HT(2C)) AGONISTS | ELI LILLY AND COMPANY (US) | 2001-10-31 | — | — | EP | disclosed |
| WO-2001009122-A2 | SEROTONERGIC BENZOFURANS | ELI LILLY AND COMPANY (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2001009111-A1 | BENZOFURYLPIPERAZINES AND BENZOFURYLHOMOPIPERAZINES: SEROTONIN AGONISTS | ELI LILLY AND COMPANY (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2000044737-A1 | AMINOALKYLBENZOFURANS AS SEROTONIN (5-HT(2C)) AGONISTS | ELI LILLY AND COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552770-B2 | Compounds for treating respiratory disease | TMEM109, SCN1A, SLC16A1 | LMNA 573/4885KDM4E 3063/4885CYP3A4 2672/4885 |
| US-12162863-B2 | Modulators of stimulator of interferon genes (STING) | STING1, IRF3, CGAS | LMNA 3267/4885KDM4E 4414/4885CYP3A4 1025/4885 |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | INMT, CARM1, KDM1B | LMNA 420/4885KDM4E 43/4885CYP3A4 2871/4885 |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | LMNA 4065/4885KDM4E 4567/4885CYP3A4 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.